- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06676137
An Observational Study of Coronary Microvascular Disease of China (CCMD)
August 19, 2025 updated by: Henan Institute of Cardiovascular Epidemiology
China Coronary Microvascular Disease(CCMD) Registry
Non-obstructive coronary heart disease refers to patients with angina pectoris without significant narrowing of the epicardial vessels.
Coronary microvascular disease(CMD) is a kind of non-obstructive coronary heart disease, and its clinical detection rate is increasing, seriously affecting the quality of life of patients, and increasing the risk of cardiovascular adverse events, but its mechanism has not been fully understood.
This study will prospectively collect patients who meet the diagnosis of CMD, observe the development and outcome of the disease, and explore its occurrence and development mechanism.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Quan Guo
- Phone Number: +8615670510031
- Email: xinyiguoquan@163.com
Study Locations
-
-
-
Zhengzhou, China, 450003
- Recruiting
- Fuwai central China cardiovascular hospotial
-
Contact:
- Quan Guo
- Phone Number: +8615670510031
- Email: xinyiguoquan@163.com
-
Principal Investigator:
- Yang Gao
-
Principal Investigator:
- Qingbo Shi
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The patient had obvious symptoms of angina pectoris, but coronary angiography showed no obvious epicardial stenosis, and auxiliary examinations such as ultrasound, CTP,CMR, PET, SPECT, and coronary function examination indicate the presence of microcirculation dysfunction
Description
Inclusion Criteria:
- Angina symptoms
- Objective evidence of myocardial ischemia
- Coronary angiography was normal,irregular tube wall, or stenosis <50%
Exclusion Criteria:
- People under the age of 18
- Non-cardiogenic chest pain and other heart conditions such as variant angina, cardiomyopathy, myocarditis or valvular heart disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Establish a Registry of CMD patients in China
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: muwei li, Ph.D, Fuwai central China cardiovascular hospotial
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 11, 2024
Primary Completion (Estimated)
October 10, 2028
Study Completion (Estimated)
October 10, 2029
Study Registration Dates
First Submitted
November 4, 2024
First Submitted That Met QC Criteria
November 4, 2024
First Posted (Actual)
November 6, 2024
Study Record Updates
Last Update Posted (Actual)
August 20, 2025
Last Update Submitted That Met QC Criteria
August 19, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HenanICE202410
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Microvascular Disease
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Lisata Therapeutics, Inc.TerminatedCoronary Microvascular Disease | Coronary Microvascular Dysfunction | Microvascular Coronary Artery DiseaseUnited States
-
Institute for Cardiovascular Diseases "Dedinje"Abbott Medical DevicesRecruitingCoronary Artery Disease | Coronary Microvascular Dysfunction | Angina, MicrovascularSerbia, Greece, Croatia, Israel, Slovenia
-
VahatiCor, Inc.RecruitingCoronary Microvascular Disease | Coronary Microvascular DysfunctionSpain, Netherlands, Poland
-
Catharina Ziekenhuis EindhovenOnze Lieve Vrouwziekenhuis AalstRecruitingCoronary Vasospasm | Microvascular Angina | Microvascular Coronary Artery Disease | Microvascular ResistanceNetherlands
-
Université Libre de BruxellesTerminatedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular DiseaseBelgium
-
Medstar Health Research InstituteRecruiting
-
Queen Mary University of LondonEchopoint Medical LtdCompletedCoronary Artery Disease | Coronary Microvascular Disease | Coronary StenosisUnited Kingdom
-
First People's Hospital of HangzhouCompletedCoronary Artery Disease | Coronary Microvascular DiseaseChina
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCoronary Artery Disease | Coronary Microvascular DiseaseUnited States